PHARMACOGENETIC ASPECTS OF COMBINED HORMONAL CONTRACEPTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The analysis of the data on safety, tolerability and acceptability of combined oral contraceptives (COCs) is of great interest. Studies shows that the features of a metabolism of a particular drug and the patient's genetics are the key to understanding the risk of side effects.

Full Text

Restricted Access

About the authors

E. V Ivanova

JCS «Moscow Laser Company» Moscow

E. A Mezhevitinova

Email: mejevitinova@mail.ru
FSBI «SCOGP n.a. V.I. Kulakov» of RMPH MD, Leading Researcher at the Scientific Policlinic Department Moscow

A. E Donnikov

FSBI «SCOGP n.a. V.I. Kulakov» of RMPH Moscow

I. G Nikitin

SBEI HPE RNSMU n.a. N.I. Pirogov of RMPH Moscow

V. N Prilepskaya

FSBI «SCOGP n.a. V.I. Kulakov» of RMPH Moscow

References

  1. Артымук Н.В., Гуляева Л.Ф., Иленко Е.В., Харенкова Е.Л. Полиморфизм ферментов метаболизма эстрогенов у женщин с гиперпластическими процессами в эндометрии в период перименопаузы. Российский вестник акушера-гинеколога. 2009;2:17.
  2. Бороян Р.Г. Клиническая фармакология для акушеров-гинекологов. 3-е изд., перераб. и доп. М., 2008. С. 169.
  3. Буеверов А.О. Лекарственные поражения печени. Избранные лекции: гастроэнтерология, хирургия, урология, неврология, кардиология. РМЖ. 2001;9:13-14.
  4. Караченцев А.Н., Кузнецова И.В. Терапия эстрогенами при артериальной гипертонии у женщин в климактерическом периоде: Обзор. Проблемы эндокринологии. 2004;49(4):51-4.
  5. Кулакова В.И., Савельева Г.М., Манухин И.Б. Гинекология - национальное руководство. М., 2009. С. 200-5.
  6. Кукес В.Г., Грачев С.В., Сычев Д.А., Раменская Г.В. Метаболизм лекарственных средств. Научные основы персонализированной медицины: руководство для врачей. М., 2008. С. 304.
  7. Межевитинова Е.А. Гормональная контрацепция у женщин, страдающих сахарным диабетом. Consilium Medicum. 2004;6(9).
  8. Прилепская В.Н., Межевитинова Е.А., Назарова Н.М., Бостанджян Л.Л. Гормональная контрацепция. М., 2011. C. 86-92.
  9. Подзолкова Н.М. Гормональная контрацепция: вопросы безопасности и переносимости. РМЖ. 2009; 17( 1 )5-10.
  10. Современные аспекты гормональной контрацепции. Серов В.Н., Михайлова О.И., Мать и дитя. Акушерство и гинекология. Специальный номер. 2008;19:12313-18.
  11. Сычев Д.А., Игнатьев И.В. Клиническая фармакогенетика. М., 2007. 248 c.
  12. Сычев Д.А., Миронова Н.А. Фармакогенетическое тестирование по CYP2D6 и CYP2C19: значение для персонализации применения лекарственных средств в клинической практике. Лаборатория. 2012;4:11-13.
  13. Cai, H., Shu X.O., Egan K.M., Cai Q., Long J.R., Gao Y.T., Zheng W. Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women. Pharmacogenet. Genom. 2008;18(8):657-64.
  14. Cavalieri E., Rogan E. Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture. Ann N. Y. Acad Sci. 2006; 1089:286-301.
  15. Chen H.Y., Chung Y.W., Lin W.Y., Chen W.C., Tsai F.J., Tsai C.H. Estrogen receptor alpha polymorphism is associated with pelvic organ prolapse risk. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2008;19(8):1159-63.
  16. Chen C., Li Y., Chen F., Pan H., Shen H., Sun Z., Wu Y., Zhou J., Ba L., Zhao J. Estrogen receptor beta genetic variants and combined oral contraceptive use as relates to the risk of hypertension in Chinese women. Arch Med Res. 2010;41 (8):599-605.
  17. Crandall C.J., Sehl M.E., Crawford S.L., Gold E.B., Habel L.A., Butler L.M., Sowers M.R., Greendale G.A., Sinsheimer J.S. Sex steroid metabolism polymorphisms and mammographie density in pre- and early peri-menopausal women. Breast Caneer Res. 2009;11(4):R51.
  18. Delort L., Satih S., Kwiatkowski F., Bignon Y.J., Bernard-Gallon D.J. Evaluation of breast eaneer risk in a multigenie model including low penetranee genes involved in xenobiotie and estrogen metabolisms. Nutr. Caneer. 2010;62:243-51.
  19. Gambaeeiani M., Ciaponi M., Cappagli B., Piaggesi L., De Simone L., Orlandi R., Genazzani A.R. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J. Clin. Endoerinol. Metab. 1997;82:414-17.
  20. Goldstein A.T., Belkin Z.R., Krapf J.M., Song W., Khera M., Jutrzonka S.L., Kim N.N., Burrows L.J., Goldstein I. Polymorphisms of the androgen reeeptor gene and hormonal eontraeeptive indueed provoked vestibulodynia. J. Sex. Med. 2014;11(11 ):2764-71.
  21. Hevir N., Sinkovee J., Rizner T.L. Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial eaneer: lower levels of CYP1B1 and inereased expression of S-COMT. Mol. Cell. Endoerinol. 2011;331 ( 1 ):158-67.
  22. Ishimoto T.M., Ali-Osman F. Allelie variants of the human glutathione S-transferase P1 gene eonfer differential eytoproteetion against antieaneer agents in Eseheriehia eoli. Pharmaeogeneties. 2002;12(7):543-53.
  23. Ito Y., Fisher C.R., et al. Moleeular basis of aromatase defieieney in an adult female with sexual infantilism and polyeystie ovaries. Proe. Natl. Aead. Sei. USA. 1993;90(24):11673-77.
  24. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influenee of eyto-ehrome P450 polymorphisms on drug therapies: pharmaeogenetie, pharmaeoepigenetie and elinieal aspeets. Pharmaeol. Ther. 2007; 116:496-526.
  25. Liehr J.G., Rieei M.J. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proe. Natl. Aead. Sei. USA. 1996;93(8):3294-96.
  26. Laehman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human eateehol-O-methyltransferase pharmaeogeneties: deseription of a funetional polymorphism and its potential applieation to neu-ropsyehiatrie disorders. Pharmaeogeneties. 1996;6(3):243-50.
  27. Martimbeau S., Tilly J.L. Physiologieal cell death in endoerine-dependent tissues: an ovarian perspeetive. Clin Endoerinol (Oxf). 1997;46:241-54.
  28. Mulatero P.1, Morra di Cella S., Veglio F. Hypertension, genotype and oral eontraeeptives. Pharmaeogenomies. 2002;3(1):57-63.
  29. Muti P., Bradlow H.L., Mieheli A., Krogh V., Freudenheim J.L., Sehunemann H.J., Stanulla M., Yang J., Sepkovie DW;Trevisan M., Berrino F. Estrogen metabolism and risk of breast eaneer: a prospective study of the :16alphahy-droxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000;11(6):635-06.
  30. Murdoeh W.J. Inhibition by oestradiol of oxidative stress-indueed apoptosis in pig ovarian tissues. J. Reprod. Fertil. 1998;114:127-130.
  31. Nguyen TT, Sehafer H, Timmesfeld N. Making medieal deeisions in dependenee of genetie baekground: estimation of the utility of DNA testing in elinieal, pharmaeo-epidemiologieal or genetie studies PMID: 23558781. Genet Epidemiol. 2013;37(4):311-22.
  32. Petry C.J., Ong K.K., Miehelmore K.F., Artigas S., Wingate D.L., Balen A.H., de Zegher F., Ibanez L., Dunger D.B. Assoeiation of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum. Reproduet. 2005;20(7): 1837-43.
  33. Piaeentini S., Polimanti R., Porreea F., Martinez-Labarga C., De Stefano G.F., Fueiarelli M. GSTT1 and GSTM1 gene polymorphisms in European and Afriean populations. Mol. Biol. Rep. 2011;38(2):1225-30.
  34. Rau T., Wohlleben G., Wuttke H., Thuerauf N., Lunkenheimer J., Lanezik M., Esehenhagen T. CYP2D6 genotype: impaet on adverse effeets and nonresponse during treatment with anti-depressants-a pilot study. Clin. Pharmaeol. Ther. 2004;75(5):386-93.
  35. Rianeho J.A., Sanudo C., Valero C., Pipaon C., Olmos J.M., Mijares V., Fernandez-Luna J.L., Zarrabeitia M.T. Assoeiation of the aromatase gene alleles with BMD: epidemiologieal and funetional evidenee. J. Bone Miner Res. 2009;24( 10):1 709-18.
  36. Sowers M.R., Wilson A.L., Kardia S.R., Chu J., Ferrell R. Aromatase gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiraeial/multiethnie, multisite study of women at midlife. Am. J. Med. 2006;119(9 Suppl. 1):S23-30.
  37. Strange R.C., Matharoo B., Faulder G.C., Jones P., Cotton W., Elder J.B., Deakin M. The human glutathione S-transferases: a case-control study of the incidence of the GST1 0 phenotype in patients with adenocarecnoma. Carcinogenesis. 1991;12(1):25-28.
  38. Swen, J.J., Nijenhuis M., de Boer A., Grandia L., Maitland-van der Zee A.H., Mulder H., Rongen G.A., van Sehaik R.H., Sehalekamp T., Touw D.J., van der Weide J., Wilffert B., Deneer V.H., Guehelaar H.J. Pharmacogenetics: from bench to byte an update of guidelines. Clin. Pharmacol. Ther. 2011;89(5): 662-73.
  39. Zhang H., Cui D., Wang B., Han Y.H., Bali mane P., Yang Z., Sinz M., Rodrigues A.D. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin. Pharmacokinet. 2007; 46:133-57.
  40. Zhu B.T., Conney A.H. Is 2-methoxyestra-diol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res. 1998;58:2269-77.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies